Yanmei Hu

Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir

A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations

Brilacidin, a COVID‐19 drug candidate, demonstrates broad‐spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell

Point-of-care SARS-CoV-2 sensing using lens-free imaging and a deep learning-assisted quantitative agglutination assay

Drug-Repurposing Screening Identified Tropifexor as a SARS-CoV-2 Papain-like Protease Inhibitor

Cytopathic Effect Assay and Plaque Assay to Evaluate in vitro Activity of Antiviral Compounds Against Human Coronaviruses 229E, OC43, and NL63

Discovery of SARS-CoV-2 Papain-like Protease Inhibitors through a Combination of High-Throughput Screening and a FlipGFP-Based Reporter Assay

The <i>in vitro</i> antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses

Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir

Enterovirus A71 antivirals: Past, present, and future

Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein

Rimantadine Binds to and Inhibits the Influenza A M2 Proton Channel without Enantiomeric Specificity

Rational design of a deuterium-containing M2-S31N channel blocker UAWJ280 with <i>in vivo</i> antiviral efficacy against both oseltamivir sensitive and -resistant influenza A viruses

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M ^pro and cathepsin L

Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors

Enterovirus D68 Antivirals: Past, Present, and Future

Development of broad-spectrum enterovirus antivirals based on quinoline scaffold

Pharmacological Characterization of the Mechanism of Action of <b>R523062</b>, a Promising Antiviral for Enterovirus D68

Validating Enterovirus D68-2A ^pro as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68-2A ^pro Inhibitor

Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68)

A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68

Discovery of Influenza Polymerase PA–PB1 Interaction Inhibitors Using an <i>In Vitro</i> Split-Luciferase Complementation-Based Assay

Identification of NMS-873, an allosteric and specific p97 inhibitor, as a broad antiviral against both influenza A and B viruses

In Vitro Pharmacokinetic Optimizations of AM2-S31N Channel Blockers Led to the Discovery of Slow-Binding Inhibitors with Potent Antiviral Activity against Drug-Resistant Influenza A Viruses

Structure–Property Relationship Studies of Influenza A Virus AM2-S31N Proton Channel Blockers

Focusing on the Influenza Virus Polymerase Complex: Recent Progress in Drug Discovery and Assay Development